Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    June 2018
  1. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    PubMed     Text format    


  2. TARAMASSO L, Montanari L, Di Biagio A
    Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment.
    AIDS. 2018;32:1202-1203.
    PubMed     Text format    


    March 2018
  3. MERCHANTE N, Rodriguez-Arrondo F, Revollo B, Merino E, et al
    Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001809.
    PubMed     Text format     Abstract available


  4. LARMARANGE J, Becquet V, Masumbuko JM, Nouaman M, et al
    Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B.
    AIDS. 2018;32:829-830.
    PubMed     Text format    


  5. VALENCIA J, Ryan P, Alvaro-Meca A, Troya J, et al
    High HIV seroconversion rate in HCV-infected drug users followed in a Harm Reduction Unit: A lost opportunity for Pre- exposure Prophylaxis.
    AIDS. 2018 Mar 20. doi: 10.1097/QAD.0000000000001806.
    PubMed     Text format     Abstract available


  6. ISMAIL MF, Wong DK, Bogoch II
    The role for hepatitis A vaccination in HIV pre-exposure prophylaxis.
    AIDS. 2018;32:675-676.
    PubMed     Text format    


    February 2018
  7. FARFOUR E, Lesprit P, Wai ACH, Mazaux L, et al
    Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage.
    AIDS. 2018;32:531-532.
    PubMed     Text format    


  8. MEDRANO LM, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, et al
    Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/HCV-coinfected patients.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001787.
    PubMed     Text format     Abstract available


  9. PRADAT P, Huleux T, Raffi F, Delobel P, et al
    Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001789.
    PubMed     Text format     Abstract available


    January 2018
  10. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
    AIDS. 2018;32:337-346.
    PubMed     Text format     Abstract available


  11. ROSSI C, Saeed S, Cox J, Vachon ML, et al
    Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.
    AIDS. 2018 Jan 23. doi: 10.1097/QAD.0000000000001750.
    PubMed     Text format     Abstract available


  12. WILLIS SJ, Cole SR, Westreich D, Edmonds A, et al
    Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.
    AIDS. 2018 Jan 13. doi: 10.1097/QAD.0000000000001745.
    PubMed     Text format     Abstract available


  13. YOSHIMURA Y, Miyata N, Komatsu H, Tachikawa N, et al
    Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
    AIDS. 2018;32:128-129.
    PubMed     Text format    


    November 2017
  14. LI F, Ma L, Feng Y, Ruan Y, et al
    HIV-1 and Hepatitis C virus selection bottleneck in Chinese people who inject drugs.
    AIDS. 2017 Nov 30. doi: 10.1097/QAD.0000000000001702.
    PubMed     Text format     Abstract available


  15. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.
    AIDS. 2017;31:2483-2492.
    PubMed     Text format     Abstract available


  16. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating HCV in difficult-to-treat HIV-coinfected patients as implemented in routine medical practice.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001699.
    PubMed     Text format     Abstract available


    October 2017
  17. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    PubMed     Text format    


    September 2017
  18. ZOBOLI F, Ripamonti D, Benatti SV, Comi L, et al
    Autoimmune hepatitis and HIV infection: two case reports and review of the literature.
    AIDS. 2017;31:2172-2175.
    PubMed     Text format    


  19. LAKE AC
    Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.
    AIDS. 2017;31:2115-2118.
    PubMed     Text format     Abstract available


  20. THORNTON AC, Jose S, Bhagani S, Chadwick D, et al
    Hepatitis B, hepatitis C and mortality among HIV-positive individuals.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001646.
    PubMed     Text format     Abstract available


  21. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001648.
    PubMed     Text format     Abstract available


    July 2017
  22. SARIS J, van den Berk G, Moha DA, van der Meer J, et al
    Successful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care.
    AIDS. 2017;31:1779-1780.
    PubMed     Text format    


  23. LEBRUN D, Hentzien M, Cuzin L, Rey D, et al
    Epidemiology of autoimmune and inflammatory diseases in a French Nationwide HIV cohort.
    AIDS. 2017 Jul 18. doi: 10.1097/QAD.0000000000001603.
    PubMed     Text format     Abstract available


  24. HOORNENBORG E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, et al
    MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
    AIDS. 2017;31:1603-1610.
    PubMed     Text format     Abstract available


  25. ZENG H, Wang L, Liu P, Liao L, et al
    Seroprevalence of hepatitis E virus in HIV-infected patients in China.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001585.
    PubMed     Text format     Abstract available


  26. SINGH KP, Crane M, Audsley J, Lewin SR, et al
    HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001574.
    PubMed     Text format     Abstract available


  27. VANHOMMERIG JW, Bezemer D, Molenkamp R, Van Sighem AI, et al
    Limited overlap between phylogenetic HIV and HCV clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001592.
    PubMed     Text format     Abstract available


    June 2017
  28. TODESCO E, Demeret S, Calin R, Roque-Afonso AM, et al
    Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS. 2017;31:1346-1348.
    PubMed     Text format    


  29. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    AIDS. 2017;31:1223-1234.
    PubMed     Text format     Abstract available


    May 2017
  30. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.
    AIDS. 2017;31:1099-1107.
    PubMed     Text format     Abstract available


  31. HOORNENBORG E, Achterbergh RCA, Schim Van Der Loeff MF, Davidovich U, et al
    Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study.
    AIDS. 2017 May 1. doi: 10.1097/QAD.0000000000001522.
    PubMed     Text format     Abstract available


    March 2017
  32. MONTES ML, Olveira A, Ahumada A, Aldamiz T, et al
    Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    AIDS. 2017 Mar 29. doi: 10.1097/QAD.0000000000001465.
    PubMed     Text format     Abstract available


  33. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001448.
    PubMed     Text format     Abstract available


  34. PRICE H, Dunn D, Zachary T, Vudriko T, et al
    Hepatitis B serological markers and plasma DNA concentrations: baseline results from the DART trial.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001454.
    PubMed     Text format     Abstract available


  35. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    HCV drives increased type I IFN-associated impairments associated to fibrosis severity in ART-treated HIV-1-HCV coinfected individuals.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001455.
    PubMed     Text format     Abstract available


  36. TOBIN SC
    Evaluating the generalizability of clinical trials of direct-acting antivirals for HIV/HCV-coinfection.
    AIDS. 2017 Mar 1. doi: 10.1097/QAD.0000000000001439.
    PubMed     Text format    


    January 2017
  37. REID M, Ma Y, Scherzer R, Price JC, et al
    Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
    AIDS. 2017;31:385-393.
    PubMed     Text format     Abstract available


  38. SORIANO V, Sherman KE, Barreiro P
    Hepatitis Delta and HIV Infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001424.
    PubMed     Text format     Abstract available


  39. PINATO DJ, Pria AD, Sharma R, Bower M, et al
    Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV co-infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001422.
    PubMed     Text format     Abstract available


  40. SEREMBA E, Ssempijja V, Kalibbala S, Gray RH, et al
    Hepatitis B incidence and prevention with antiretroviral therapy among HIV positive individuals in Rakai, Uganda.
    AIDS. 2017 Jan 17. doi: 10.1097/QAD.0000000000001399.
    PubMed     Text format     Abstract available



  41. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe.
    AIDS. 2017;31:127-135.
    PubMed     Text format     Abstract available


  42. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Text format     Abstract available


    December 2016
  43. PETERS L, Cozzi-Lepri A
    Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?
    AIDS. 2016 Dec 21. doi: 10.1097/QAD.0000000000001378.
    PubMed     Text format     Abstract available


  44. MERCHANTE N, Rivero-Juarez A, Tellez F, Merino D, et al
    Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    November 2016
  45. YOUNAS M, Carrat F, Finge S, Desaint C, et al
    Immune activation, smoking, and vaccine response.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    October 2016
  46. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.
    AIDS. 2016;30:2469-2476.
    PubMed     Text format     Abstract available


    September 2016
  47. SCHERZER R, Heymsfield SB, Rimland D, Powderly WG, et al
    Association of serum albumin and AST with 5-year all-cause mortality in HIV/HCV coinfection and HIV monoinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  48. THORNE C, Turkova A, Indolfi G, Venturini E, et al
    Co-infection with HIV and HCV in 229 children and young adults living in Europe.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  49. NEWSUM AM, Ho CK, Lieveld FI, Van De Laar TJ, et al
    The hepatitis C virus NS3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    August 2016
  50. MILLARD JD, Henry J, Rizvi SS, Nelson M, et al
    Direct-acting antivirals for acute hepatitis C in HIV-infected MSM.
    AIDS. 2016;30:2137-9.
    PubMed     Text format    


  51. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  52. GOWDA C, Brown TT, Compher C, Forde KA, et al
    Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    July 2016
  53. CACHAY E, Soriano V
    Is HIV still a special population for the treatment of hepatitis C?
    AIDS. 2016;30:2001-3.
    PubMed     Text format    


  54. CHEW KW, Bhattacharya D
    Virologic and immunologic aspects of HIV-HCV coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    June 2016
  55. HAGAN H, Jordan AE, Cleland CM
    Response to the calculation of population attributable fractions of risk factors for hepatitis C transmission: authors' reply.
    AIDS. 2016;30:1685.
    PubMed     Text format    


  56. SCHMIDT AJ, Bremer V
    Response to the calculation of population attributable fractions (PAFs) of risk factors for hepatitis C transmission.
    AIDS. 2016;30:1683-4.
    PubMed     Text format    


  57. SMOLDERS EJ, Kanter CT, Grintjes K, D'Avolio A, et al
    Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
    AIDS. 2016;30:1491-3.
    PubMed     Text format    


  58. GARCIA M, Le Moal G, Godet C, Beraud G, et al
    First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS. 2016;30:1487-8.
    PubMed     Text format    


    May 2016
  59. KHELOUFI F, Bellissant E, Cotte L, Poizot-Martin I, et al
    eGFR but not SLC polymorphisms influences anemia in HIV-HCV co-infected patients treated with boceprevir- or telaprevir-based therapy (ANRS HC26 and HC27 Study).
    AIDS. 2016.
    PubMed     Text format     Abstract available


    April 2016
  60. GARCIA-ALVAREZ M, Berenguer J, Jimenez-Sousa MA, Vazquez-Moron S, et al
    Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients.
    AIDS. 2016;30:1069-1074.
    PubMed     Text format     Abstract available


    March 2016
  61. AUDSLEY J, Bent SJ, Littlejohn M, Avihingsanon A, et al
    Effects of long-term tenofovir-based cART in HIV-HBV co-infection on persistent HBV viremia and the role of HBV quasispecies diversity.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    February 2016
  62. ROSSI C, Cox J, Cooper C, Martel-Laferriere V, et al
    Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV co-infected patients.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  63. CHILDS K, Taylor C, Dieterich D, Agarwal K, et al
    Directly acting antivirals (DAAs) for HCV arrive in HIV/HCV co-infected patients: from 'mind the gap' to 'where's the gap?'
    AIDS. 2016.
    PubMed     Text format    


    January 2016
  64. BEGUELIN C, Vazquez M, Moradpour D, Sahli R, et al
    Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
    AIDS. 2016;30:530-3.
    PubMed     Text format    


  65. JIMENEZ-SOUSA MA, Berenguer J, Garcia-Alvarez M, Gutierrez-Rivas M, et al
    Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients.
    AIDS. 2016;30:465-70.
    PubMed     Text format     Abstract available


  66. MANDORFER M, Schwabl P, Steiner S, Scheiner B, et al
    Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  67. GRANT JL, Hawkins C, Brooks H, Palella FJ Jr, et al
    Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    AIDS. 2016;30:93-8.
    PubMed     Text format     Abstract available


  68. TOWNSEND K, Petersen T, Gordon LA, Kohli A, et al
    Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
    AIDS. 2016;30:261-6.
    PubMed     Text format     Abstract available


  69. FAGIUOLI S, Puoti M, Rizzardini G
    Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders?
    AIDS. 2016;30:323-5.
    PubMed     Text format    


  70. PARK LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, et al
    Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.
    AIDS. 2016;30:273-91.
    PubMed     Text format     Abstract available


    December 2015
  71. LIU L, Nardo D, Li E
    CD4+ T-cell recovery with suppressive ART induced rapid sequence evolution in HCV envelope but not NS3.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    November 2015
  72. PETERS MG, Bacchetti P, Boylan R, French AL, et al
    Enhanced liver fibrosis marker as a non-invasive predictor of mortality in HIV/HCV-coinfected women from the women's Interagency HIV study.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    September 2015
  73. REAL LM, Herrero R, Rivero-Juarez A, Camacho A, et al
    IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
    AIDS. 2015;29:1895-7.
    PubMed     Text format     Abstract available


    June 2015
  74. THIO CL, Smeaton L, Hollabaugh K, Saulynas M, et al
    Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    AIDS. 2015;29:1173-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: